| 摘要 |
FIELD: veterinary virology and biotechnology. ^ SUBSTANCE: claimed vaccine contains antigenic material from PRRS virus strain, reproduced in passaged cell culture Marc-145 and inactivated with aminoethylethyleneimine (AEEI), antigenic material from PPVI virus strain reproduced in passaged YPK cell culture and inactivated with AEEI, and oil adjuvant in effective ratio. Vaccine represents white or white-rose emulsion. Vaccine is intramuscularly (behind ear) administered to animal in dose of 2 cm3 independently of age thereof. Immunity in vaccinated animals appears over 21-30 days after vaccination and remains for 6 months or more. Vaccine of present invention induces high levels of antibodies against PRRS and PPVI and provides durable passive immunity in young stocks up to 20-25-days age. ^ EFFECT: innoxious vaccine useful in animal protection of neonatal age from field viral PRRS and PPVI agents. ^ 14 cl, 8 tbl, 11 ex |
